Objective: A rat model of left atrial stenosis-associated pulmonary hypertension due to left heart diseases was prepared to elucidate its mechanism.
See Editorial Commentary page 1754.
Pulmonary hypertension (PH) due to left heart disease (LHD) is the most common form of PH. PH-LHD belongs to the second group in the World Health Organization classification that was updated in Nice. 1, 2 Primary LHD consists of heart failure (HF) with reduced or preserved ejection fraction and severe left-sided valvular diseases, such as mitral valve stenosis. It has been recently reported that the presence of PH-LHD in patients with left
From the Departments of a Cell Physiology and HF is associated with a worse prognosis than in those without PH-LHD. 3 Despite its prevalence and significance, there has been little research on PH-LHD. Moreover, no effective drug regimen has been established, and treatment is usually for the underlying LHD. For example, phospodiesterase-5 (PDE-5) inhibitors are clinically used for patients with PH-LHD [4] [5] [6] ; however, the efficacy of PDE-5 inhibitors against PH-LHD is controversial 7 because the use of pulmonary vasodilators elevates left atrial pressure in those with PH-LHD, which may worsen congestive HF.
In addition, the pathophysiology of PH in PH-LHD should be different from that of pulmonary arterial hypertension (PAH), in which there is remodeling of the pulmonary artery (PA). 8 A main cause of the lack of clarity surrounding the treatment and mechanism in PH-LHD could be the absence of an appropriate PH-LHD animal model. The objective of this study is to establish a PH-LHD rat model based on the hemodynamic mechanism accompanying left atrial stenosis (LAS)-induced left atrial pressure elevation and observe changes in the lung to elucidate the mechanism of PH-LHD.
MATERIALS AND METHODS Experimental Design
Five-week-old Sprague-Dawley rats were purchased from the same trader (Sankyo Labo Service Corporation, Tokyo, Japan) and installation date, and randomly divided into LAS and sham-operated control (SOC) groups. For example, we purchased 2 rats for a 1-day surgical procedure and then divided them into 1 for LAS and 1 for SOC. The protocol of this study is shown in Figure 1 . Animals were intubated with Angiocath 18G under 2% isoflurane anesthesia, and respiration was managed using a Harvard rodent ventilator (Harvard Apparatus, Holliston, Mass), in which the tidal volume was set at 10 mL/g, and the respiratory rate was set at 100/min in accordance with a previous study. 9 The thymus was removed by lateral thoracotomy through the fifth intercostal region. Because the thymus was stuck with the epicardium, we needed to remove the thymus. The heart was identified, and an interrupted suture was applied to the left atrial appendage using 5-0 Prolene (Johnson and Johnson, New Brunswick, NJ) in the LAS group (n ¼ 5). The thread of the interrupted suture was pulled up to lift the heart, and the left atrium (LA) was half clipped under direct vision using Horizon Ligating Clips (Teleflex, Morrisville, NC) and a Horizon Manual-Load ligating Clip Applier (Teleflex). The thorax was then closed. The procedure is shown in Videos 1 and 2. When left ventricular (LV) inflow velocity was 2.0 m/s or higher on echocardiography at 2 weeks after surgery, the rats were subjected to further analysis. Because LV inflow velocity of 2.0 m/s or higher is considered significant in human mitral valve stenosis, 10 we used the LV inflow velocity of 2.0 m/s for a cutoff value to estimate the PH-LHD model rats. In the SOC group (n ¼ 5), only thymectomy was performed and the thorax was then closed. We set the observation period for 10 weeks after surgery, because Wang and colleagues 11 previously reported that aortic constriction caused PH-LHD 9 weeks after surgery. All rats were maintained at 22 C AE 2 C under a 12-hour light/dark cycle following the National Institute of Health guidelines for animal experiments. This experiment was performed after approval by the Institutional Animal Care and Use Committee of The Jikei University (2015-118C1).
Echocardiography
Echocardiography was performed at 2, 4, 6, and 10 weeks after surgery in both groups, and the rats were sedated with 1.5% isoflurane using a 13-MHz transducer from the GE Vivid i8 ultrasound system (GE Healthcare, Madison, Wis). The parameters of echocardiography were also used in a previous study. 9 
Cardiac Catheterization
Cardiac catheterization was performed at 10 weeks after surgery under 2% isoflurane anesthesia using artificial respiration management. The artificial respiration conditions were the same as those during surgery. We used 1.9F Rodent PV Catheters (Transonic Systems Inc, Ithaca, NY) and the ADVantage PV System (Transonic Systems Inc) for measuring pressure and volume of right ventricles (RVs) and LV, and then analyzed the data using the analysis software Labscribe2 (iWorx, Dover, NH). RV and LV pressures were measured by directly placing the catheter into each ventricle after thoracotomy. After completion of catheterization, the animals were euthanized with pentobarbital and the organs were excised. Estimated LA pressure was calculated by adding LV end-diastolic pressure and the pressure gradient between LV and LA. The pressure gradient between LV and LA was measured by echocardiography using Bernoulli's principle from the blood flow velocity in the clip region. LV end-diastolic pressure was measured by cardiac catheterization.
Histologic Examination and Measurement of Venous Wall Thickness
The excised lung tissue was subjected to hematoxylin-eosin, Masson-trichrome, and Elastica van Gieson staining. Each sample was observed under a light microscope at 40 times magnification, and 8 (100-300 mm) pulmonary veins (PVs) were randomly selected per sample and photographed. In the photographed images, the venous and venous luminal areas were measured using Image-Pro Premier 9.1 (Media Cybernetics, Rockville, Md) ( Figure E1 ). This method also was used by Nishimura and colleagues, 12 who calculated the venous wall thickness by subtracting the venous lumen from the venous area.
Immunostaining of Lung Tissue
Immunostaining of a-smooth muscle actin (SMA) (mouse anti-human antibody, M0851, DakoCytomation, Glostrup, Denmark), proliferating cell nuclear antigen (PCNA) (mouse anti-human antibody, M0879, DakoCytomation), Ephrin B2 (rabbit anti-mouse antibody, NBP1-84830, Novus Biologicals, Littleton, Colo), and EphB4 (goat anti-human antibody, sc7285, Santa Cruz Biotechnology, Dallas, Tex) was performed in 5 rats each in the LAS and SOC groups.
DNA Microarray Analysis
For Oligo DNA microarray analysis, 3D-Gene Rat Oligo chip 20k (Toray Industries Inc, Tokyo, Japan) was used. Two lung samples from each group were combined for comparison. Total RNA was labeled with Cy5 using the Amino Allyl MessageAMP II aRNA Amplification Kit (Applied Biosystems, Foster City, Calif). The Cy5-labeled aRNA pools and hybridization buffer were hybridized for 16 hours. The hybridization was performed using the supplier's protocols (www.3d-gene.com). Hybridization signals were scanned using ScanArray Express Scanner (PerkinElmer, Waltham, Mass) and processed by GenePixPro version5.0 (Molecular Devices Inc, Sunnyvale, Calif). The raw data intensities greater than 2 standard deviations of the background signal intensity were considered to be valid. Detected signals for each gene were normalized using a standard normalization method.
Real-Time Polymerase Chain Reaction Analysis
Both isolation of total RNA from pooled tissues and generation of cDNA and reverse transcription-polymerase chain reaction analysis were performed as described previously. 9 Transforming growth factor-b1 (TGF-b1), aSMA, vascular endothelial growth factor (VEGF), endothelin-1 (ET-1), endothelin type A receptor, endothelin type B receptor, procollagen I, and connective tissue growth factor expression levels in the lung were measured in the LAS (n ¼ 5) and SOC (n ¼ 5) groups using real-time polymerase chain reaction. The primer nucleotide 
Western Blot Analysis
Total protein was extracted from the lung and used for Western blot analyses including antibodies against ET-1 (mouse anti-human antibody, ab2786, Abcam, Cambridge, UK), TGF-b (rabbit anti-human antibody, #3711, Cell Signaling, Danvers, Mass), and b-actin (mouse anti-human antibody, 122M4782, Sigma-Aldrich, St Louis, Mo), as described previously. 9 
Statistical Analysis
Statistical analyses were performed using Prism 7 (GraphPad Software, Inc, La Jolla, Calif). All data are presented as the mean AE standard deviation or interquartile range. Two-way repeated-measures analysis of variance followed by Sidak's post hoc test was performed to assess echocardiographic finding. Other analyses were performed using the Mann-Whitney U test.
RESULTS

The Left Atrial Stenosis Group Developed Pulmonary Hypertension and Left Heart Disease
Rats that underwent LAS developed a dilated LA, marked congestion, and pleural effusion 10 weeks after surgery ( Figure 2 , A and B). We confirmed at autopsy that the circumflex coronary artery was not clipped in the LAS group. The summary of heart weight measurement and hemodynamic parameters is shown in Table 1 that in the SOC group (Table 1 ). The ratio of lung to body weights was significantly increased in the LAS groups.
The RV pressure was significantly increased in the LAS group, as the representative pressure waveforms are shown in Figure E2 . Although we could not directly measure PA pressure, the RV systolic pressure/LV systolic pressure ratio in the LAS group was significantly increased to 0.52 (interquartile range, 0.54-0.60), indicating moderate PH (Table 1 ). In addition, the end-diastolic LV and RV pressures were significantly higher in the LAS group compared with the SOC group (Table 1) . Representative images of echocardiography at 10 weeks after surgery are shown in Figure 2 and Videos 3 and 4. In the long-axis and 4-chamber views, an artifact produced by clipping was noted in the LA in the LAS group. Color Doppler imaging revealed that LV inflow velocity was accelerated from the clipped region. In the short-axis view, the interventricular septum flattened with an increase in wall thickness, suggesting that RV pressure was increased. Pulmonary venous blood flow showed continuous waves of 2 animals in the LAS group.
Changes in the echocardiographic findings after surgery are shown in Figure 3 . The LV inflow velocity was approximately 2 times higher in the LAS group than in the SOC group. Left ventricular ejection fraction was gradually decreased in the LAS group, but it was not significant. Cardiac output was significantly decreased in the LAS group. LA dimensions were enlarged at 6 and 10 weeks after surgery in the LAS group compared with the SOC group.
The Medial Wall of the Pulmonary Vein Was Thickened in the Left Atrial Stenosis Group
We found pulmonary arteriovenous congestion and venous dilatation in the LAS group (Figures 4 and E3) . On Elastica van Gieson staining, the isolated medial hypertrophy of muscular pulmonary arteries with an outer diameter of 100 to 300 mm was observed in the 4 rats of LAS group, but that no neointimal lesion developed (Figure 4, C) .
In addition, the venous wall thickness and dimension were significantly increased in the PVs with an outer diameter of 100 to 150 mm in the LAS group (Figure 4 , V and W). aSMA staining was positive in these pulmonary venous walls, and the smooth muscle thickness was increased in the LAS group compared with the SOC group ( Figure 4, F and H) . PCNA immunostaining identified PCNA-positive cells more in the PV smooth muscle of the LAS group than in the SOC group, suggesting an increase in proliferative ability in the LAS group (Figure 4 , X) (15.55 AE 5.18 and 7.51 AE 3.98, respectively, P < .01). Ephrin B2 was expressed in the endothelial cells of the PA and vein of each group, but no EphB4 expression was observed in both groups (Figure 4 , M-T).
Transforming Growth Factor-b and Endothelin Signal Pathways Could Be Enhanced in the Left Atrial Stenosis Group DNA microarray analysis identified the genes with expression levels were 4 times or greater different between the LAS and the SOC groups ( Figure 5 and Table E2 ). Pathway analysis identified that the TGF-b signaling pathway was an enhanced pathways in the LAS group ( Figure E4 ). The TGF-b signaling pathway is known as a therapeutic target in patients with PH. In addition, the pathway promotes the tissue fibrosis. Thus, we evaluated mRNA expression of TGF-b1, connective tissue growth factor, procollagen I (barometer of fibrosis), aSMA (activated by TGFb1), VEGF (factor of angiogenesis), ET-1 (regulated by TGFb1), and endothelin type A and endothelin type B receptor (receptors for ET-1).
On real-time polymerase chain reaction, the aSMA and VEGF expression levels were higher in the LAS than in the SOC group (LAS: 6.98 AE 1.37 and 2.87 AE 0.67, respectively, P < .01; SOC: 1.0 AE 0.40 and 1.0 AE 0.21, respectively, P <.01). TGF-b1, ET-1, endothelin type A, endothelin type B, connective tissue growth factor, and procollagen I mRNA expression were not different between 2 groups ( Figure 6, A-H) . Western blot analyses revealed that TGF-b1 and ET-1 protein expression were significantly increased in the LAS group compared with the SOC group ( Figure 6 , I-K).
DISCUSSION Left Atrial Stenosis-Induced Pulmonary Hypertension Left Heart Disease Model Is a Unique Pulmonary Hypertension Model
The most important finding in the present study is that progressive medial hypertrophy was observed in the PVs of a PH-LHD rat model, which resulted from PV congestion that prevented PV flow by clipping the LA lesion. In this PH-LHD rat model, moderate medial hypertrophy also was observed in the PA. To the best of our knowledge, this is the first animal model of PH-LHD induced by LAS.
The pathophysiology of PH-LHD is different from the other kinds of PH. 13 Thus, appropriate animal models are required to elucidate its mechanism for the detailed research. There are 2 PH-LHD models reported: the pulmonary vein stenosis (PVS) model using piglets and the aortic banding rat model.
Kato and colleagues 14 applied banding to the PVs in an in vivo experiment using a PVS model in piglets, in which an increase in the wall thickness of the upstream PV in the lung was also observed in this model, which is similar to the observations in our study. In a LAS-induced PH-LDH model, we also found that medial hypertrophy was more marked in smaller PVs and those further away from the LAS lesion (Figure 4, U) . This indicates that the influence of LAS gradually expands upstream in the lung. aSMA and TGF-b were also upregulated in the PVs in both studies. Therefore, our rat model phenotype of LAS-induced PH-LDH closely resembles that of the piglet model of PVS, although PH induction was not clearly demonstrated in the PVS model. However, our rat model of LASinduced PH-LDH has some advantages over a piglet PVS model: The surgical procedure to generate LAS is easier and less complicated than that of PVS, and the rat is a widely used experimental animal with a lower cost. Aortic banding was also used to prepare a PH-LHD rat model in some previous studies. 11, 15, 16 These models demonstrated mild PH and left HF. Wang and colleagues 11 reported that pulmonary arterial medial thickening and biventricular cardiac hypertrophy are observed, and PCNA-positive cells are noted in vascular SMCs in their aortic banding models. These results are also observed in our study. However, this method is not ideal because it has several disadvantages. PH caused by aortic stenosis is relatively rare in humans. PH-LDH caused by mitral valve lesions is more common, and its hemodynamics are similar to those of our LAS model. 17 In addition, the aortic banding model also initially promotes left HF, and pulmonary congestion occurs thereafter. Therefore, the pathophysiology of PH-LHD by aortic banding is complicated compared with LAS-induced PH-LHD.
Animal models of PAH such as monocrotaline-treated rats, hypoxic rats, and Sugen5416 VEGF antagonist-treated rats have been established. Moreover, 2-hit models combining 2 elements (eg, hypoxia and Sugen5416) have been developed as a model of PAH. In these rats, pathologic findings are similar to those of PAH in humans (ie, PAH begins with medial hypertrophy of small pulmonary arteries, and plexiform lesions then appear after neointimal lesions). [18] [19] [20] [21] [22] [23] However, except for hypoxia, the effects of monocrotaline and Sugen5416 are artificial and different from the cause of PAH in humans. These studies focused on pulmonary arterial changes, not on the PV. Developing pulmonary congestion and pulmonary edema is the most critical difference between PH-LHD and PAH. Although we did not measure hydrostatic pressure of the PV, it should be high in a PH-LHD model based on its hemodynamics and the findings of pleural effusion. Pulmonary congestion could increase the alveolar-arterial oxygen difference, which is not usually observed in a PAH model. Although these differences should affect PH progression, there are few insights into how the mechanism and development of PH in PH-LHD and PAH are different. Therefore, LAS in the present study should be a reasonable and feasible method to investigate the mechanisms of PH-LHD.
Pulmonary Vein Remodeling in Pulmonary Hypertension Left Heart Disease
Endo and colleagues 24 demonstrated that central PV obstruction is known to trigger pulmonary venous arterialization, progressive medial hypertrophy, and intimal fibrosis of the affected venous tree. Because we found that medial hypertrophy was developed and aSMA and PCNA were positive in the wall of the PV in the LAS group, we think that the veins are arterialized. Although the mechanism of pulmonary venous arterialization still remains unclear. It has been reported that arterialization of the systemic veins is caused by shear stress of pressure loads induced by an arteriovenous shunt. Ephrin B2 is specifically expressed in arterial endothelial cells and SMCs, whereas EphB4 is specifically expressed in veins during development. EphB4 is known to be downregulated in arterialized veins. 25 Considering that this mechanism is involved in arterialization of the PV in the present study, we examined immunostaining of Ephrin B2 and EphB4 in the lung of our LAS-induced PH-LHD model (Figure 4, M-T) . However, EphB4 was not expressed in the SOC and LAS groups. We currently do not have a reasonable explanation for the discrepancy between our results and those of previous studies in systemic veins. Hall and colleagues 26 reported that Ephrin and Eph are mainly expressed during an embryonic period and involved in differentiation into the PA and vein, but their expressions are decreased after birth, suggesting that the involvement of Ephrin in arterialization of the PV is less likely.
We found that TGF-b and ET-1 expression levels were enhanced in the LAS lung on DNA microarray and Western blot analyses. Although real-time polymerase chain reaction analysis did not show the significant difference of them in the LAS and SOC groups, we think that it must be due to the small number of sample sizes. It has been reported that TGF-b and ET-1 are involved in PAH progression and enhanced in pulmonary arteries in response to shear stress, hypoxia, and thrombin. 27, 28 In addition to these molecules, we also found that many genes that are changed in patients with PAH and animal models were similarly changed in the present DNA microarray analysis.
Clinical Implications
Although several drugs such as endothelin receptor antagonists, prostacyclin, and PDE-5 inhibitors are clinically used for patients with PAH, there is little consensus for treatment of PH-LHD because they have different pathophysiology compared with PAH. It should be noted that pediatric patients with cor triatriatum or who undergo supra-annular mitral valve replacement with LA reduction exhibit similar pathophysiology with the LAS model rat. As indicated earlier, the PV hydrostatic pressure is increased in most of patients with PH-LHD. In addition, some of these patients exhibit LV failure and low cardiac output. In the present study, ET-1 was increased in the PH-LHD model, suggesting that endothelin receptor antagonists may be effective for PH-LHD. Endothelin receptor antagonists inhibit ventricular remodeling and improve exercise tolerance in an animal model of HF. 29 An endothelin receptor antagonist, tezosentan, was reported to increase cardiac output and reduce the pulmonary arterial wedge pressure and pulmonary and systemic vascular resistance in patients with acute HF. 30 However, the efficacy of long-term administration of endothelin receptor antagonists against chronic HF was not observed in the Research on Endothelin Antagonists in Chronic Heart Failure (REACH-1) study. 31 Perez-Villa and colleagues 32 recently reported that administration of an endothelin receptor antagonist, bosentan, for 4 months significantly reduced pulmonary vascular resistance in patients with PH who were indicated for cardiac transplantation.
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PDE-5 inhibitors have been used mainly as a pulmonary vasodilator for PH-LHD. [4] [5] [6] However, the efficacy of PDE-5 inhibitors against PH-LHD is controversial, because Hoendermis and colleagues 7 reported that the PDE-5 inhibitor sildenafil did not improve pulmonary arterial pressure or clinical symptoms in patients with PH-LHD. 7 Therefore, the effect of these drugs in our LAS-induced PH-LHD rat model requires further study.
Study Limitations
One of the limitations in the present study is that we could not measure the LA and pulmonary capillary wedge pressure by catheterization because of bleeding. Therefore, we used the estimated LA pressure. Although the value of this estimated pressure was overestimated, we could not quantitatively investigate how LA pressure affects the pulmonary venous arterialization. Thus, the transpulmonary gradient is the important prognostic factor for patients with PH-LHD, 33 and detailed catheterization to estimate PV pressure is required in a future study. We also found that RV and LV end-diastolic pressures were increased in the LAS group, suggesting that elevated RV pressure may affect the diastolic LV function. This should be taken account for further investigation using this model.
It should be noted that we used the entire lung containing the artery, vein, bronchus, and alveolar epithelial cells for expression analyses. Further research is required to investigate a specific target that plays a critical role in development of PH-LHD, using pure PVs by cell sorting and immunohistochemical analyses.
The severity of PH was moderate, and only medial lesions were noted and no neointimal lesion was observed FIGURE 6 . mRNA and protein expression levels of the lung in the SOC and LAS groups. Real-time polymerase chain reaction analysis assessed the mRNA expression levels of (A) TGF-b1, (B) aSMA, (C) VEGF, (D) ET-1, (E) endothelin type A, (F) endothelin type B, (G) connective tissue growth factor, and (H) procollagen I. The expression levels of aSMA and VEGF were significantly increased in the LAS than in the SOC group. I, Western blot analyses revealed that the expression levels of (J) TGF-b1 and (K) ET-1 proteins were significantly increased in the LAS group. SOC, Sham-operated control; LAS, left atrium stenosis; TGF-b, transforming growth factor-b; aSMA, alpha smooth muscle actin; VEGF, vascular endothelial growth factor; ET-1, endothelin 1; ET A , endothelin receptor type A; ET B , endothelin receptor type B; CTGF, connective tissue growth factor. **P<.01, upper horizontal bar: third quartile, middle horizontal bar: middle quartile, lower horizontal bar: first quartile. = in the PVof the LAS rat. Because intimal lesions are usually thickened in patients with pulmonary veno-occlusive disease or PVS, we could not evaluate its mechanism by using this model. 34 Obviously, the obstruction in such diseases occur early during fetal development, and therefore, longer observation should be required to investigate the effect of the intimal lesions of the PV using this model.
CONCLUSIONS
We established a novel and feasible PH-LHD model in which venous arterialization was observed in rats. The LAS-induced PH-LHD model allows us to further investigate the mechanism of PH-LHD and treatments such as endothelin receptor antagonists.
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